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Background
In Italy, the estimated cost of chronic migraine (CM) is
around six billion euros per year (Agenas, 2011) consid-
ering the health costs, the loss in working productivity
and quality of life.
The efficacy of BT-A in the prophylactic treatment of
CM has been demonstrated [1]. However, BT-A therapy is
expensive and the limited health service resource may
raise the question of the cost/benefit ratio. Ruggeri et al
[1] carried out a study to provide an estimate of the incre-
mental cost-effectiveness ratio of the treatment of CM
with BT-A 2 . They compared the benefit as extrapolated
from the PREEMPT data with those of a population of
CM from the METEOR study, as well as with those of an
actual population of CM from a district of Rome [1]. In
the present study we compared actual costs and benefit in
a CM population before and after BT-A treatment.
Methods
We recruited CM patients with or without MOH,
according to the ICHD-3beta classification. All patients
were injected using the standard protocol for CM. At
follow-ups, planned every 12 weeks, headache clinical
features (including quality of life scales), direct health
costs and indirect costs due to loss of work productivity
[1] supported within 3 months, were recorded.
Results
We consecutively enrolled 34 patients with CM, (19 with
MOH). To date, we have considered the results at
24 weeks (T2). Nine patients (26%) dropped out because
of side effects or poor compliance (5 at T1, 4 at T2). In
the nineteen patients, who completed the T2 follow-up
(56%), we observed a statistical clinical benefit (p < 0.001)
in headache features (29% less in attack frequency, 39%
less in attack duration, 21% less in pain intensity, 63% less
in drug intake) and a significant reduction of pain-killer
costs per month (-75%) and a decrease of working produc-
tivity loss (-28%). Moreover, MSQ and MIDAS were also
significantly improved.
Conclusions
After the first 24 weeks, BT-A was effective in both clinical
CM features, as well as the decrease of the amount of its
direct and indirect health costs. These preliminary data
seem to confirm the findings from studies of probabilistic
estimates although they will need to be confirmed in a
larger population and a longer follow-up.
Written informed consent to publication was obtained
from the patient(s).
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